1
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
3
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa
K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al: Dacomitinib
versus gefitinib as first-line treatment for patients with
EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A
randomised, open-label, phase 3 trial. Lancet Oncol. 18:1454–1466.
2017. View Article : Google Scholar : PubMed/NCBI
|
6
|
Soria JC, Ohe Y, Vansteenkiste J,
Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura
F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated
advanced non-small-cell lung cancer. N Engl J Med. 378:113–125.
2018. View Article : Google Scholar : PubMed/NCBI
|
7
|
Kimura H, Kasahara K, Kawaishi M, Kunitoh
H, Tamura T, Holloway B and Nishio K: Detection of epidermal growth
factor receptor mutations in serum as a predictor of the response
to gefitinib in patients with non-small-cell lung cancer. Clin
Cancer Res. 12:3915–3921. 2006. View Article : Google Scholar : PubMed/NCBI
|
8
|
Kimura H, Ohira T, Uchida O, Matsubayashi
J, Shimizu S, Nagao T, Ikeda N and Nishio K: Analytical performance
of the cobas EGFR mutation assay for Japanese non-small lung
cancer. Lung Cancer. 83:329–333. 2014. View Article : Google Scholar : PubMed/NCBI
|
9
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kosaka T, Yatabe Y, Endoh H, Kuwano H,
Takahashi T and Mitsudomi T: Mutations of the epidermal growth
factor receptor gene in lung cancer: Biological and clinical
implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar : PubMed/NCBI
|
11
|
Tokumo M, Toyooka S, Kiura K, Shigematsu
H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, et al:
The relationship between epidermal growth factor receptor mutations
and clinicopathologic features in non-small cell lung cancers. Clin
Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
|
12
|
Sonobe M, Manabe T, Wada H and Tanaka F:
Mutations in the epidermal growth factor receptor gene are linked
to smoking-independent, lung adenocarcinoma. Br J Cancer.
93:355–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
14
|
Mitsudomi T, Kosaka T and Yatabe Y:
Biological and clinical implications of EGFR mutations in lung
cancer. Int J Clin Oncol. 11:190–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Kobayashi Y and Mitsudomi T: Not all
epidermal growth factor receptor mutations in lung cancer are
created equal: Perspectives for individualized treatment strategy.
Cancer Sci. 107:1179–1186. 2016. View Article : Google Scholar : PubMed/NCBI
|
16
|
Riely GJ, Pao W, Pham D, Li AR, Rizvi N,
Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M and Miller VA:
Clinical course of patients with non-small cell lung cancer and
epidermal growth factor receptor exon 19 and exon 21 mutations
treated with gefitinib or erlotinib. Clin Cancer Res. 12:839–844.
2006. View Article : Google Scholar : PubMed/NCBI
|
17
|
Jackman DM, Yeap BY, Sequist LV, Lindeman
N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS,
et al: Exon 19 deletion mutations of epidermal growth factor
receptor are associated with prolonged survival in non-small cell
lung cancer patients treated with gefitinib or erlotinib. Clin
Cancer Res. 12:3908–3914. 2006. View Article : Google Scholar : PubMed/NCBI
|
18
|
Hirsch FR, Varella-Garcia M, Cappuzzo F,
McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky
K, West H, et al: Combination of EGFR gene copy number and protein
expression predicts outcome for advanced non-small-cell lung cancer
patients treated with gefitinib. Ann Oncol. 18:752–760. 2007.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Lin MT, Mosier SL, Thiess M, Beierl KF,
Debeljak M, Tseng LH, Chen G, Yegnasubramanian S, Ho H, Cope L, et
al: Clinical validation of KRAS BRAF, and EGFR mutation detection
using next-generation sequencing. Am J Clin Pathol. 141:856–866.
2014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Xu X, Yang Y, Li H, Chen Z, Jiang G and
Fei K: Assessment of the clinical application of detecting EGFR,
KRAS, PIK3CA and BRAF mutations in patients with non-small cell
lung cancer using next-generation sequencing. Scand J Clin Lab
Invest. 76:386–392. 2016. View Article : Google Scholar : PubMed/NCBI
|